Tilray | TRLY - Bruttoergebnis Vom Umsatz

Aktienkurs
8.54
Täglich Wechseln
-0.58 -6.36%
Monatlich
-17.57%
Jährlich
818.28%
Q1 Prognose
8.33




Bruttoergebnis Vom Umsatz Veränderung Datum
Acasti Pharma USD 75K 30K 2021-03
Akebia Therapeutics USD 47.28M 1.7M 2025-12
Alaunos Therapeutics USD -1.13M 1.11M 2024-09
Aurora Cannabis CAD 46.62M 14.33M 2025-12
Avita Medical AUD 14.31M 639K 2025-12
Canopy Growth CAD 21.47M 434K 2025-12
Cronos Group USD 16.19M 34.52M 2025-12
Dianthus Therapeutics USD 284K 112K 2025-12
Divis Laboratories Ltd INR 16.59B 2.05B 2025-12
Ionis Pharmaceuticals USD 195M 40M 2025-12
IQVIA Holdings USD 1.12B 32M 2025-12
Knight Therapeutics CAD 64.72M 8.91M 2025-12
Moderna USD 226M 583M 2025-12
Organigram Holdings CAD 23.32M 8.52M 2025-12
Organon & Co USD 854M 3M 2025-12
Revvity USD 421.66M 47.06M 2025-12
Tectonic Therapeutic USD 0 0 2025-03
Tilray USD 57.47M 10.16M 2025-06
Viatris USD 1.15B 223.6M 2025-12
Xeris Pharmaceuticals USD 72.15M 8.77M 2025-12
Zealand Pharma A/S 68.91M 19.35M 2025-12